Enterprise Value
4.403B
Cash
286.3M
Avg Qtr Burn
-72.19M
Short % of Float
9.97%
Insider Ownership
2.61%
Institutional Own.
-
Qtr Updated
03/31/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Emflaza (deflazacort) Details Duchenne muscular dystrophy | Approved Quarterly sales | |
Evrysdi (riskiplam) Details SMA (Spinal muscular atrophy) | Approved Quarterly sales | |
Translarna (ataluren) Details DMD (Duchenne muscular dystrophy) | Approved Quarterly sales | |
Upstaza (PTC-AADC) Details Aromatic L-amino acid decarboxylase deficiency | BLA Submission | |
Sepiapterin (PTC923) Details Phenylketonuria | Phase 3 Update | |
Vatiquinone (PTC743) Details Friedreich’s Ataxia | Phase 3 Update | |
Vatiquinone (PTC743) Details Epilepsy, Mitochondrial disease | Phase 2/3 Data readout | |
PTC518 Details Huntington's disease | Phase 2 Data readout | |
PTC299 (DHODH inhibitor) Details COVID-19 | Failed Discontinued |